Ongoing Clinical Studies in Bladder Cancer

Cretostimogene grenadenorepvec (CG0070) is currently being evaluated in multiple studies including Phase 1b/2, Phase 2, and Phase 3 studies in the U.S. in BCG unresponsive NMIBC and MIBC. Two studies are actively recruiting. Studies are on-going in South Korea, Japan, China, Taiwan, Australia, and Canada.




Safety and Efficacy

Phase 2, US only



Phase 3

Phase 3, Global (US, Japan, South Korea, Taiwan, Australia, Canada)


Phase 2, CG0070 Combined With Pembrolizumab

Phase 2, Global (US, South Korea)

Active, Not Recruiting


Phase 1 Study With Nivolumab Ineligible Cisplatin with MIBC

Phase 1b/2, US Only


Patients and Urologists interested in participating should contact:

JoAnn Horn
phone: 516-456-1415

Expanded Patient Access

How Patients can Access the on-going Studies

CG Oncology is currently focused on conducting clinical research that evaluates the safety and effectiveness of investigational cretostimogene grenadenorepvec (CG0070) in Non-Muscle Invasive Bladder Cancer (NMIBC). Our clinical trials program is the primary way for interested patients to access cretostimogene grenadenorepvec at this time. We encourage patients to speak with their healthcare providers about participating in a clinical trial and may also find information on our current clinical studies on on-going clinical trials

As a general policy, CG Oncology does not anticipate providing investigational medicines to patients until our clinical data suggests that the therapy has provided evidence of safety and efficacy as defined by the U.S. Food and Drug Administration. As a result, CG Oncology believes the most appropriate way to access our investigational therapy is through participating in one of our clinical trials.


CG Oncology is eager to partner with companies who share our passion for improving patients and their loved one’s lives. Collaborations could be in R&D, business development or clinical trials. Our partners include:

  • Merck
  • Bristol Myers Squibb
  • Roche
  • Kissei Pharmaceutical Co.
  • LEPU Medical Holdings
  • FUJIFILM Diosynth Biotechnologies

If you are interested in becoming a partner with us, please contact us at